Happening Now: The AACR Annual Meeting! #AACR2024
LC is excited to participate in the meeting and share the latest information on the patient experience, “Cancer related fatigue and the additive effect of treatment in the context of lymphoma and CLL: An analysis of Lymphoma Coalition’s 2022 Global Patient Survey.”
📌 Poster Presentation Details:
🕒 Time: Apr. 8, 2024, 9:00 AM - 12:30 PM
📍 Session PO.SHP01.01 - Science and Health Policy
To view the full abstract visit: https://t.co/l6TYFomOi8
Pacylex Pharmaceuticals Reports Zelenirstat Disrupts Oxidative Phosphorylation in Cancer Cells at AACR 2024 - Defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study
https://t.co/HZSK7cKTfo.
Honored to be a presenting part of this great community dedicated to science for patients. Thanks for your interest in our company! https://t.co/jBLA49zvOH
Announcing Pacylex at AACR. Poster Title: N-myristoylation inhibitor zelenirstat: new mechanistic insights and efficacy signals from a first in human phase I study. https://t.co/jBLA49zvOH
Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. https://t.co/LQhX0RTAs3
Target Oncology interviewed Dr. Randeep Sangha, our Principal Investigator for zelenirstat in our Phase 1/2 clinical study: Zelenirstat Shows Evidence of Clinical Benefit Across Advanced Cancers https://t.co/tcG0jyhhWn
Our CEO was at ASCO-GI presenting our results in patients with gastrointestinal cancers. He shared the Phase 1 clinical experience with zelenirstat, our first in class, oral, cancer medicine in Phase 2. Take a look. https://t.co/rM8JSnV2ZS
Best regards,
Michael
We’re excited to attend the MedInvest Oncology Investor Conference this week! Our CEO, Michael Weickert will be sharing the Company's Phase 1 study results for zelenirstat, a first in class oral therapy in development for patients with hematologic and solid tumors.
Pacylex Pharmaceutical's CEO Michael Weickert will discuss exciting progress on the PCLX-001 clinical development program at the 2023 BIO International Convention June 5-8, 2023, at the Boston Convention & Exhibition Center.
https://t.co/9Ctyfvpp4L
#BIO2023@IAmBiotech
ASH is working to advance research & care in #hematology. On #WorldBloodCancerDay, we're proud to share our committment to #hemeonc through our dedication to improving the use of #immunotherapies 🩸🧬 Learn more: https://t.co/rUX7A9H1sR